ABSTRACT
Objective: To find out response of Gefitinib in terms of overall survival in advanced non small cell carcinoma lung progressed after primary treatment. Methods: It is a retrospective study of clinical data experienced with use of Gefitinib as a second line treatment of advanced non small cell carcinoma lung progressed after primary treatment from period of March 2007 to March 2009 in Burdwan Medical College and Hospital at Department of Radiotherapy (Oncology). Results: Among patients treated with Gefitinib (n – 37) median overall survival was 9.6 months whereas, patients treated with placebo median survival was 5.3 months. There is a significant survival advantage ( p < 0.001) in Gefitinib group. Conclusion: Gefitinib is a well tolerated drug and it has a significant survival advantage in advanced non small cell carcinoma lung progressive after primary treatment.